Screening for prostate cancer: To the editor

Screening for prostate cancer: To the editor

Bibliographic Details
Main Authors:	Carlsson, S, Vickers, A, Lilja, H, Hugosson, J
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
by: Carlsson, S, et al.
Published: (2012)

Prostate cancer: estimating the benefits of PSA screening.
by: Vickers, A, et al.
Published: (2009)

Urological cancer: Time for another rethink on prostate cancer screening.
by: Vickers, A, et al.
Published: (2012)

Screening for prostate cancer: early detection or overdetection?
by: Vickers, A, et al.
Published: (2012)

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
by: Hugosson, J, et al.
Published: (2000)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Lead time associated with screening for prostate cancer.
by: Törnblom, M, et al.
Published: (2004)

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial.
by: Hugosson, J, et al.
Published: (2010)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
by: Bergdahl, A, et al.
Published: (2009)

Screening for prostate cancer: an update.
by: Shariat, S, et al.
Published: (2008)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
by: Bruun, L, et al.
Published: (2005)

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
by: Aus, G, et al.
Published: (2007)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
by: Hugosson, J, et al.
Published: (2003)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
by: Hugosson, J, et al.
Published: (2003)

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
by: Aus, G, et al.
Published: (2005)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
by: Khatami, A, et al.
Published: (2007)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands.
by: Auvinen, A, et al.
Published: (2009)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
by: Savage, C, et al.
Published: (2010)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
by: Khatami, A, et al.
Published: (2007)

Five genetic variants associated with prostate cancer.
by: Vickers, A, et al.
Published: (2008)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
by: Hugosson, J, et al.
Published: (2004)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
by: Lilja, H, et al.
Published: (2008)

Predicting prostate cancer many years before diagnosis: how and why?
by: Vickers, A, et al.
Published: (2012)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
by: Roobol, M, et al.
Published: (2012)

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
by: de Koning, H, et al.
Published: (2002)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.
by: Hugosson, J, et al.
Published: (2001)

We need a better marker for prostate cancer. How about renaming PSA?
by: Vickers, A, et al.
Published: (2012)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
by: Vickers, A, et al.
Published: (2011)

Screening and prostate-cancer mortality in a randomized European study.
by: Schröder, F, et al.
Published: (2009)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
by: Vickers, A, et al.
Published: (2009)